Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Olema Pharmaceuticals Inc (OLMA)

Olema Pharmaceuticals Inc (OLMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,465,981
  • Shares Outstanding, K 87,157
  • Annual Sales, $ 0 K
  • Annual Income, $ -162,450 K
  • EBIT $ -179 M
  • EBITDA $ -178 M
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.80

Options Overview Details

View History
  • Implied Volatility 92.77% (-44.82%)
  • Historical Volatility 107.81%
  • IV Percentile 18%
  • IV Rank 15.04%
  • IV High 416.48% on 11/14/25
  • IV Low 35.47% on 09/02/25
  • Expected Move (DTE 24) 1.53 (9.23%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 388
  • Volume Avg (30-Day) 180
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 14,095
  • Open Int (30-Day) 37,983
  • Expected Range 15.05 to 18.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.52
  • Number of Estimates 6
  • High Estimate $-0.48
  • Low Estimate $-0.58
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.11 +26.47%
on 03/24/26
17.47 -5.07%
on 04/20/26
+2.50 (+17.76%)
since 03/20/26
3-Month
12.99 +27.64%
on 03/09/26
27.86 -40.49%
on 01/22/26
-10.14 (-37.95%)
since 01/20/26
52-Week
3.89 +326.22%
on 06/13/25
36.26 -54.27%
on 12/16/25
+12.16 (+275.11%)
since 04/17/25

Most Recent Stories

More News
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits...

OLMA : 16.58 (-1.43%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment...

OLMA : 16.58 (-1.43%)
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (“Olema” or “the Company”) (NASDAQ: OLMA ) for violations...

OLMA : 16.58 (-1.43%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)
Olema Oncology Announces Departure of Chief Operating and Financial Officer

SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc.  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...

OLMA : 16.58 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California....

See More

Key Turning Points

3rd Resistance Point 18.42
2nd Resistance Point 17.94
1st Resistance Point 17.26
Last Price 16.58
1st Support Level 16.10
2nd Support Level 15.63
3rd Support Level 14.95

See More

52-Week High 36.26
Fibonacci 61.8% 23.89
Fibonacci 50% 20.07
Last Price 16.58
Fibonacci 38.2% 16.25
52-Week Low 3.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.